Aurobindo Pharma Ltd.’s wholly-owned subsidiary, Eugia Pharma Specialities Ltd., has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Pazopanib Tablets (200 mg). These tablets are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets (200 mg) by Novartis Pharmaceuticals Corporation.
| Company | Value | Change | %Change |
|---|
The product is expected to launch in the fourth quarter of FY25.
According to IQVIA, the approved product has an estimated market size of $106 million for the twelve months ending October 2024.
Pazopanib is used to treat certain types of cancer.
Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad.
The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.
Shares of Aurobindo Pharma Ltd. are currently trading 0.73% lower at Rs 1,250.20. The stock is up 15% so far in 2024.
